FRM
SGYP

Fox Run Management’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Fox Run Management’s Portfolio SGYP Stock Details SGYP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-11,500
Closed -$54K – 913
2017
Q1 		$54K Buy
+11,500
New +$66.7K 0.02% 544

Other funds holding SGYP

PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Fox Run Management's SGYP Position: Q2 2017 in Review

Fox Run Management sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q2 2017, closing a stake of 11,500 shares — an estimated $54K sold.

Fox Run Management first reported a position in SGYP in Q1 2017 and held it in 1 quarter. The position peaked at $54K in Q1 2017. 146 funds tracked by Wall St. Rank hold SGYP as of Q2 2017.

  • Fox Run Management reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q2 2017 after selling out during the quarter.
  • Fox Run Management sold 11,500 Synergy Pharmaceuticals, Inc Common Stock shares in Q2 2017, an estimated $54K.
  • Fox Run Management first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q1 2017 and held it in 1 quarter.
  • Fox Run Management's Synergy Pharmaceuticals, Inc Common Stock position peaked at $54K in Q1 2017.
  • 146 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q2 2017.

Based on Fox Run Management's 13F filing for Q2 2017, filed 10 Jul 2017.